Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
Eleanor Watts
(1)
,
Aurora Perez-Cornago
(1)
,
Georgina Fensom
(1)
,
Karl Smith-Byrne
(2)
,
Urwah Noor
(1)
,
Colm Andrews
(1)
,
Marc Gunter
(2)
,
Michael Holmes
(1)
,
Richard Martin
(3)
,
Konstantinos Tsilidis
(4)
,
Demetrius Albanes
(5)
,
Aurelio Barricarte
(6)
,
H Bas Bueno-De-Mesquita
(7)
,
Barbara Cohn
,
Mélanie Deschasaux-Tanguy
(8)
,
Niki Dimou
(2)
,
Luigi Ferrucci
(9)
,
Leon Flicker
(10)
,
Neal Freedman
(5)
,
Graham Giles
(11)
,
Edward Giovannucci
(12)
,
Christopher Haiman
(13)
,
Graham Hankey
(10)
,
Jeffrey Holly
(3)
,
Jiaqi Huang
(5)
,
Wen-Yi Huang
(5)
,
Lauren Hurwitz
(5)
,
Rudolf Kaaks
(14)
,
Tatsuhiko Kubo
(15)
,
Loic Le Marchand
(16)
,
Robert Macinnis
(11)
,
Satu Männistö
(17)
,
E Jeffrey Metter
(18)
,
Kazuya Mikami
,
Lorelei Mucci
(12)
,
Anja Olsen
(19)
,
Kotaro Ozasa
(20)
,
Domenico Palli
,
Kathryn Penney
(12)
,
Elizabeth Platz
(21)
,
Michael Pollak
(22)
,
Monique Roobol
(23)
,
Catherine Schaefer
,
Jeannette Schenk
(24)
,
Pär Stattin
(25)
,
Akiko Tamakoshi
(26)
,
Elin Thysell
(27)
,
Chiaojung Jillian Tsai
(28)
,
Mathilde Touvier
(8)
,
Stephen van den Eeden
(29)
,
Elisabete Weiderpass
(2)
,
Stephanie Weinstein
(5)
,
Lynne Wilkens
(16)
,
Bu Yeap
(10)
,
Rosalind Eeles
,
Christopher Haiman
,
Zsofia Kote-Jarai
,
Fredrick Schumacher
,
Sara Benlloch
,
Ali Amin Al Olama
,
Kenneth Muir
,
Sonja Berndt
,
David Conti
,
Fredrik Wiklund
,
Stephen Chanock
,
Ying Wang
,
Catherine Tangen
,
Jyotsna Batra
,
Judith Clements
,
Naomi Allen
,
Timothy Key
,
Ruth Travis
1
Nuffield Department of Population Health [Oxford]
2 CIRC - IARC - Centre International de Recherche contre le Cancer - International Agency for Research on Cancer
3 University of Bristol [Bristol]
4 Imperial College London
5 NCI-NIH - National Cancer Institute [Bethesda]
6 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
7 RIVM - National Institute for Public Health and the Environment [Bilthoven]
8 EREN [CRESS - U1153 / UMR_A 1125] - Nutritional Epidemiology Research Team | Equipe de Recherche en Epidémiologie Nutritionnelle
9 NIA - National Institute on Aging [Bethesda, USA]
10 UWA - The University of Western Australia
11 Melbourne School of Population and Global Health [Melbourne]
12 Harvard T.H. Chan School of Public Health
13 Keck School of Medicine [Los Angeles]
14 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
15 Hiroshima University
16 University of Hawaii
17 FIHW - Finnish Institute for Health and Welfare
18 UTHSC - The University of Tennessee Health Science Center [Memphis]
19 Aarhus University Hospital
20 RERF - Radiation Effects Research Foundation [Hiroshima City, Japan]
21 Johns Hopkins Bloomberg School of Public Health [Baltimore]
22 McGill University = Université McGill [Montréal, Canada]
23 Erasmus MC - Erasmus University Medical Center [Rotterdam]
24 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
25 Uppsala Universitet [Uppsala]
26 Hokkaido University [Sapporo, Japan]
27 Umeå University, Sweden
28 MSKCC - Memorial Sloan Kettering Cancer Center
29 UC San Francisco - University of California [San Francisco]
2 CIRC - IARC - Centre International de Recherche contre le Cancer - International Agency for Research on Cancer
3 University of Bristol [Bristol]
4 Imperial College London
5 NCI-NIH - National Cancer Institute [Bethesda]
6 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
7 RIVM - National Institute for Public Health and the Environment [Bilthoven]
8 EREN [CRESS - U1153 / UMR_A 1125] - Nutritional Epidemiology Research Team | Equipe de Recherche en Epidémiologie Nutritionnelle
9 NIA - National Institute on Aging [Bethesda, USA]
10 UWA - The University of Western Australia
11 Melbourne School of Population and Global Health [Melbourne]
12 Harvard T.H. Chan School of Public Health
13 Keck School of Medicine [Los Angeles]
14 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
15 Hiroshima University
16 University of Hawaii
17 FIHW - Finnish Institute for Health and Welfare
18 UTHSC - The University of Tennessee Health Science Center [Memphis]
19 Aarhus University Hospital
20 RERF - Radiation Effects Research Foundation [Hiroshima City, Japan]
21 Johns Hopkins Bloomberg School of Public Health [Baltimore]
22 McGill University = Université McGill [Montréal, Canada]
23 Erasmus MC - Erasmus University Medical Center [Rotterdam]
24 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
25 Uppsala Universitet [Uppsala]
26 Hokkaido University [Sapporo, Japan]
27 Umeå University, Sweden
28 MSKCC - Memorial Sloan Kettering Cancer Center
29 UC San Francisco - University of California [San Francisco]
Eleanor Watts
- Fonction : Auteur
- PersonId : 1343558
- ORCID : 0000-0001-9229-2589
Aurora Perez-Cornago
- Fonction : Auteur
- PersonId : 793941
- ORCID : 0000-0002-5652-356X
Michael Holmes
- Fonction : Auteur
- PersonId : 1351369
- ORCID : 0000-0001-6617-0879
Barbara Cohn
- Fonction : Auteur
Mélanie Deschasaux-Tanguy
- Fonction : Auteur
- PersonId : 183648
- IdHAL : melanie-deschasaux
- ORCID : 0000-0002-3359-420X
- IdRef : 236007823
Leon Flicker
- Fonction : Auteur
- PersonId : 1351370
- ORCID : 0000-0002-3650-0475
Graham Giles
- Fonction : Auteur
- PersonId : 780114
- ORCID : 0000-0003-4946-9099
Edward Giovannucci
- Fonction : Auteur
- PersonId : 1351371
- ORCID : 0000-0002-6123-0219
Jiaqi Huang
- Fonction : Auteur
- PersonId : 1351372
- ORCID : 0000-0002-7808-9477
Wen-Yi Huang
- Fonction : Auteur
- PersonId : 1210034
- ORCID : 0000-0002-4440-3368
Kazuya Mikami
- Fonction : Auteur
Anja Olsen
- Fonction : Auteur
- PersonId : 757529
- ORCID : 0000-0003-4788-503X
Kotaro Ozasa
- Fonction : Auteur
- PersonId : 1351373
- ORCID : 0000-0002-5637-1383
Domenico Palli
- Fonction : Auteur
Elizabeth Platz
- Fonction : Auteur
- PersonId : 1351374
- ORCID : 0000-0003-3676-8954
Catherine Schaefer
- Fonction : Auteur
Pär Stattin
- Fonction : Auteur
- PersonId : 1351375
- ORCID : 0000-0002-8306-0687
Mathilde Touvier
- Fonction : Auteur
- PersonId : 757411
- ORCID : 0000-0002-8322-8857
- IdRef : 11033082X
Elisabete Weiderpass
- Fonction : Auteur
- PersonId : 1146551
- ORCID : 0000-0003-2237-0128
Rosalind Eeles
- Fonction : Auteur
Christopher Haiman
- Fonction : Auteur
Zsofia Kote-Jarai
- Fonction : Auteur
Fredrick Schumacher
- Fonction : Auteur
Sara Benlloch
- Fonction : Auteur
Ali Amin Al Olama
- Fonction : Auteur
Kenneth Muir
- Fonction : Auteur
Sonja Berndt
- Fonction : Auteur
David Conti
- Fonction : Auteur
Fredrik Wiklund
- Fonction : Auteur
Stephen Chanock
- Fonction : Auteur
Ying Wang
- Fonction : Auteur
Catherine Tangen
- Fonction : Auteur
Jyotsna Batra
- Fonction : Auteur
Judith Clements
- Fonction : Auteur
Naomi Allen
- Fonction : Auteur
Timothy Key
- Fonction : Auteur
Ruth Travis
- Fonction : Auteur
Résumé
Abstract Background Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. Methods Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. Results In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. Conclusions These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.
Domaines
Sciences du Vivant [q-bio]
Origine : Fichiers éditeurs autorisés sur une archive ouverte